The GSK-3 inhibitors lithium chloride and valproate are already in clinical use, and the above studies indicate that a combination of these agents and a RARα agonist may enhance the effectiveness of differentiation therapy for both ATRA-sensitive and insensitive AML. The gene discussed is RARA; the disease is acute myeloid leukemia.